Clinical trial
Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response…
NCT00411450 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00411450 |
|---|---|
| Title | Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment |
| Official title | Multi Center, Open Label, Single Arm Trial Evaluating Panitumumab in Combination With FOLFIRI Therapy Following First Line FOLFOX and Bevacizumab Treatment of Metastatic Colorectal Cancer |
| Acronym | PRECEPT |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colon Cancer, Colorectal Cancer, Rectal Cancer, Cancer, Metastatic Cancer, Metastatic Colorectal Cancer, Oncology |
| Intervention type | Biological, Drug |
| Interventions | Panitumumab, FOLFIRI |
| Enrollment | 116 |
| Start date | Nov 1, 2006 |
| Primary completion | Jan 1, 2009 |
| Completion | Oct 1, 2010 |
| First posted | Dec 14, 2006 |
| Last update posted | Feb 15, 2016 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: